In recent years, we have developed experimental procedures adopted from studies of normal perception in order to investigate relative impairments in components of spatial cognition in focal and diffuse brain-damaged patients. This methodology has enabled us to isolate striking dissociation in visuospatial components in subgroups of patients with Alzheimer's disease (AD). For instance, we found that """"""""High Spatial"""""""" AD patients (i.e., patients with better block constructions than naming on clinical tests) were not free from spatial impairment. These patients exhibited a pronounced deficit in perceiving visual details (i.e., local elements) even though their perception of global shapes was considerably better. In contrast, we found that """"""""High Verbal"""""""" AD patients (i.e., patients with better naming than block constructions) were impaired in perceiving global shapes in the face of considerably better perception of visual details. An """"""""Equal"""""""" AD subgroup (i.e., patients with equivalent impairments in naming and block constructions) exhibited similar levels of dysfunction in both global and local perception (Massman et al., in press). We propose to extend these studies by investigating (1) neurocognitive mechanisms that may underlie the dissociations of visual perception in AD subgroups (e.g., the AD subgroups may differ in their ability to perceive different spatial frequencies); 2) longitudinal changes in the visual-perceptual and visual memory deficits in AD subgroups; 3) relationships between our measures of spatial cognition and neuroanatomical changes as assessed by MRI morphometric indices and, when available, postmortem neuropathological tests among AD subgroups who display differential spatial deficits (e.g., in terms of types of naming errors). These studies may lead to (1) a more accurate characterization of differential spatial deficits in AD subgroups; (2) future development of more sensitive clinical tests for early detection of perceptual deficits in AD patients; and (3) a better understanding of brain mechanisms related to spatial cognition.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG005131-15
Application #
6267255
Study Section
Project Start
1998-04-15
Project End
1999-03-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
15
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of California San Diego
Department
Type
DUNS #
077758407
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Graves, Lisa V; Holden, Heather M; Van Etten, Emily J et al. (2018) New Yes/No Recognition Memory Analysis on the California Verbal Learning Test-3: Clinical Utility in Alzheimer's and Huntington's Disease. J Int Neuropsychol Soc 24:833-841
Kirson, Noam Y; Scott Andrews, J; Desai, Urvi et al. (2018) Patient Characteristics and Outcomes Associated with Receiving an Earlier Versus Later Diagnosis of Probable Alzheimer's Disease. J Alzheimers Dis 61:295-307
Barnes, Josephine; Bartlett, Jonathan W; Wolk, David A et al. (2018) Disease Course Varies According to Age and Symptom Length in Alzheimer's Disease. J Alzheimers Dis 64:631-642
Fong, Lauren K; Yang, Max M; Dos Santos Chaves, Rodrigo et al. (2018) Full-length amyloid precursor protein regulates lipoprotein metabolism and amyloid-? clearance in human astrocytes. J Biol Chem 293:11341-11357
Edmonds, Emily C; Ard, M Colin; Edland, Steven D et al. (2018) Unmasking the benefits of donepezil via psychometrically precise identification of mild cognitive impairment: A secondary analysis of the ADCS vitamin E and donepezil in MCI study. Alzheimers Dement (N Y) 4:11-18
Spencer, Brian; Brüschweiler, Sven; Sealey-Cardona, Marco et al. (2018) Selective targeting of 3 repeat Tau with brain penetrating single chain antibodies for the treatment of neurodegenerative disorders. Acta Neuropathol 136:69-87
Pottier, Cyril; Zhou, Xiaolai; Perkerson 3rd, Ralph B et al. (2018) Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurol 17:548-558
Burke, Shanna L; Maramaldi, Peter; Cadet, Tamara et al. (2018) Decreasing hazards of Alzheimer's disease with the use of antidepressants: mitigating the risk of depression and apolipoprotein E. Int J Geriatr Psychiatry 33:200-211
Weintraub, Sandra; Besser, Lilah; Dodge, Hiroko H et al. (2018) Version 3 of the Alzheimer Disease Centers' Neuropsychological Test Battery in the Uniform Data Set (UDS). Alzheimer Dis Assoc Disord 32:10-17
Qian, Winnie; Fischer, Corinne E; Schweizer, Tom A et al. (2018) Association Between Psychosis Phenotype and APOE Genotype on the Clinical Profiles of Alzheimer's Disease. Curr Alzheimer Res 15:187-194

Showing the most recent 10 out of 914 publications